演題抄録

International Symposium

開催概要
開催回
第51回・2013年・京都
 

Preventing Cervical Cancer: The Australian HPV Vaccination Program

演題番号 : IS2-1

[筆頭演者]
Gerard V. Wain:1 

1:Westmead Hospital, Department of Gynecology Oncology, Australia

 

Cervical cancer prevention with conventional cytological surveillance has been a remarkably successful strategy in Australia, which now has the lowest mortality from cervical cancer anywhere in the world.This success has come despite initial ignorance of the viral etiology of the disease and any true understanding of the natural history of HPV infection of the cervix. Our knowledge, understanding and technology have changed however and Australia faced the challenges of incorporating this new information into its public health program. in 2006, health economic modelling showed that the introduction of a universal HPV vaccination program would be both cost effective and cost-saving if associated with changes to the screening program. The HPV vaccination started in 2007 and initially offered free quadrivalent HPV vaccine to all girls aged 12 years as part of an ongoing program and a catch up program for girls and women aged from 13 to 26 years. The program was accompanied by a broad public education program and resulted in very high coverage, especially in the school based program. The results of this mass vaccination program are now evident, with dramatic reductions in genital condyloma, the first clinical manifestation of HPV related disease, in the vaccinated age group. There is also early evidence of a reduction in high grade cervical abnormalities. The program has now been extended to include boys as well, anticipating a drop in the range of HPV related diseases. The program in Australia has also confirmed the safety of this vaccine on a population basis. The Australian experience confirms the WHO recommendation to include HPV vaccination as part of any national vaccination scheme.

前へ戻る